Literature DB >> 14582077

MLL-rearranged leukemias: insights from gene expression profiling.

Scott A Armstrong1, Todd R Golub, Stanley J Korsmeyer.   

Abstract

Gene expression analysis of human leukemias has provided insight into disease classification and mechanisms of oncogenesis. Its success is particularly evident for acute leukemias with rearrangement of the mixed lineage leukemia (MLL) gene on chromosome 11q23. Unlike most other recurrent translocations, MLL rearrangements are found in leukemias classified as acute myelogenous leukemia (AML) or acute lymphoblastic leukemia (ALL). In addition, MLL-rearranged leukemias often express both myeloid- and lymphoid-associated genes. These unusual characteristics have generated much interest in the cell of origin and the mechanism of transformation by MLL rearrangements. Here we review insights gained from characterization of MLL-rearranged human leukemias by genome-wide expression profiling and compare these to data from model systems.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14582077     DOI: 10.1016/s0037-1963(03)00196-3

Source DB:  PubMed          Journal:  Semin Hematol        ISSN: 0037-1963            Impact factor:   3.851


  22 in total

Review 1.  DNA microarrays in the diagnosis and management of acute lymphoblastic leukemia.

Authors:  Adolfo A Ferrando; A Thomas Look
Journal:  Int J Hematol       Date:  2004-12       Impact factor: 2.490

2.  Therapy-related acute myeloid leukemia 6 years after clonal detection of inv(11)(q21q23) and MLL gene rearrangement.

Authors:  Naoko Takei; Kazumi Suzukawa; Harumi Yamamoto Mukai; Takayoshi Itoh; Yasushi Okoshi; Yasuhiro Yoda; Toshiro Nagasawa
Journal:  Int J Hematol       Date:  2006-04       Impact factor: 2.490

3.  Analysis of the Hox epigenetic code.

Authors:  Zoheir Ezziane
Journal:  World J Clin Oncol       Date:  2012-04-10

Review 4.  Epigenetic changes in the myelodysplastic syndrome.

Authors:  Jean-Pierre Issa
Journal:  Hematol Oncol Clin North Am       Date:  2010-04       Impact factor: 3.722

5.  AKT/FOXO signaling enforces reversible differentiation blockade in myeloid leukemias.

Authors:  Stephen M Sykes; Steven W Lane; Lars Bullinger; Demetrios Kalaitzidis; Rushdia Yusuf; Borja Saez; Francesca Ferraro; Francois Mercier; Harshabad Singh; Kristina M Brumme; Sanket S Acharya; Claudia Scholl; Claudia Schöll; Zuzana Tothova; Eyal C Attar; Stefan Fröhling; Ronald A DePinho; Scott A Armstrong; D Gary Gilliland; David T Scadden
Journal:  Cell       Date:  2011-09-02       Impact factor: 41.582

Review 6.  Two decades of leukemia oncoprotein epistasis: the MLL1 paradigm for epigenetic deregulation in leukemia.

Authors:  Bin E Li; Patricia Ernst
Journal:  Exp Hematol       Date:  2014-09-28       Impact factor: 3.084

Review 7.  The Hox genes and their roles in oncogenesis.

Authors:  Nilay Shah; Saraswati Sukumar
Journal:  Nat Rev Cancer       Date:  2010-04-01       Impact factor: 60.716

Review 8.  Epigenetic aspects of MDS and its molecular targeted therapy.

Authors:  Jumpei Yamazaki; Jean-Pierre J Issa
Journal:  Int J Hematol       Date:  2012-10-10       Impact factor: 2.490

9.  Development of a high-throughput screening-compatible assay for the discovery of inhibitors of the AF4-AF9 interaction using AlphaScreen technology.

Authors:  Venita Gresham Watson; Katherine M Drake; Yu Peng; Andrew D Napper
Journal:  Assay Drug Dev Technol       Date:  2013-05       Impact factor: 1.738

Review 10.  The role of CALM-AF10 gene fusion in acute leukemia.

Authors:  D Caudell; P D Aplan
Journal:  Leukemia       Date:  2007-12-20       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.